ClinicalTrials.Veeva

Menu
T

The Retina Partners | Encino, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
Faricimab
Lampalizumab
KHK4951
APL-2
Pegcetacoplan
Aflibercept
KUS121
Galegenimab
GB-102

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 30 total trials

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting
Diabetic Retinopathy
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Intravitreal Ranibizumab 0.5 mg Injection

Central retinal artery occlusion (CRAO) is an ophthalmologic emergency which leads to severe and permanent vision loss. There is no evidence-based th...

Enrolling
Central Retinal Artery Occlusion
Drug: KUS121 high dose
Drug: Sham procedure

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Active, not recruiting
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Ranibizumab refill exchange

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling
Diabetic Macular Edema
Drug: Faricimab

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Enrolling
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

Trial sponsors

Roche logo
Genentech logo
A
Kyowa Kirin logo
AbbVie logo
Allergan logo
G
K
N
U

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems